Fed. Circ. Ruling Takes 'Blocking Patents' To New Places
The Federal Circuit's recent ruling invalidating patents on Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra could expand the impact of so-called blocking patents and may make it easier to show an...To view the full article, register now.
Already a subscriber? Click here to view full article